Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
News|Articles|May 7, 2018
Lonza to Invest in Mid-Scale Biologics, Cell Therapy Manufacturing
Author(s)Pharmaceutical Technology Editors
Lonza announces addition of mid-scale biologics manufacturing capacity and cell-therapy suites at Portsmouth, NH site.
Advertisement
Lonza Pharma & Biotech announced plans to add mid-scale mammalian capacity and cell-therapy suites at the company’s Portsmouth, NH facility. The investment was announced in a press statement on May 4, 2018.
The company plans to install multiple 6000-L bioreactors with construction expected to start in late 2018. The hybrid facility will feature full-suite process analytic technology, multi-variate analysis, and single-use technologies in an existing building.
Lonza also announced the installation of multiple cell-therapy suites at the Portsmouth site. In February 2018, the company identified Portsmouth as a clinical and commercial manufacturing center for cell therapies, providing customers access to facilities for Phase I through to commercial manufacturing in one location. The facility is expected to be operational by late 2018.
Source:
Advertisement
Related to this article
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
2
Germany’s Medical Biotechnology Sector is Flourishing
3
First-in-Human Trial Speed: Why FDA Trails China
4
Formulation Strategies for Next-Generation Multiagonists
5